The INHALE Initiative

Our flagship initiative is to develop a smart opioid inhaler that fits in the palm of your hand. When you press your thumb on the sensor it will authenticate you and release a pre-measured dose of fast-acting prescription opioid. Because it measures the dose, we believe you will be less likely to overdose. It will make you wait between doses to prevent abuse, and it will taper you off at the end of your prescription in order to reduce the effects of withdrawal.

Opioid users are excited about our product!

How do opioid users feel about INHALE?

Paul Maxwell

Paul Maxwell became addicted to opioids, and in his own words, “went through hell.” When he heard about our INHALE initiative, he offered to bravely share his story and his opinion on our device.

What are we building?

We’re building a smart opioid inhaler with biometric authentication. It would be prescribed instead of pills, which are so easily abused. We are designing our inhaler to:

  • authenticate the user with a thumbrint before each dose is released
  • dispense pre-measured doses
  • limit the number of doses per window of time
  • tapers off dosing at the end of the prescription to prevent dependence and withdrawal
  • generate patient compliance for the physician
  • be small enough to fit in a pocket or purse
  • be discrete so it can be used anywhere, looking like a sleek vape
  • can contain an entire prescription without refilling
  • refillable and reusable across multiple prescriptions

Can opioids be inhaled safely?

Eleven clinical studies demonstrate the efficacy of inhaled opioids, showing them to be faster-acting, as efficacious as IV (intravenous) administration, and with fewer side-effects.

PMID: 26143313

Efficacy and safety of nebulized morphine given at 2 different doses compared to IV titrated morphine in trauma pain

PMID: 25027194

Nebulized fentanyl vs intravenous morphine for ED patients with acute limb pain: a randomized clinical trial

PMID: 17898251

Randomized clinical trial of nebulized fentanyl citrate versus i.v. fentanyl citrate in children presenting to the emergency department with acute pain

PMID: 15963870

Nebulized Versus Subcutaneous Morphine for Patients with Cancer Dyspnea: A Preliminary Study

PMID: 8866928

Systemic absorption of nebulized morphine compared with oral morphine in healthy subjects.

Study NCT03580187

Nebulized Morphine in Chest Trauma Patients: A Prospective Study

Study NCT01123551

Nebulized Morphine Versus Intravenous Morphine in the Management of Post Traumatic Pain in Emergency Department (ED)

Study NCT00020618

Inhaled Morphine Compared With Morphine By Mouth in Treating Cancer Patients With Breakthrough Pain

Study NCT00286065

Study to Determine Efficacy and Safety of Inhaled AeroLEF in the Treatment of Acute Post-op Pain in Adult Patients Undergoing Elective Orthopedic Surgery

Study NCT00791804

A Phase II Study Evaluating Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500mcg/mL) for Post-Operative Pain in Adults After ACL Knee Surgery

Study NCT00794209

Phase lb, Five Period Crossover, Open-Label Study Evaluating a Single Dose Administration of 3mL or 5mL of Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 Mcg/mL), Delivered by up to Four Aerosol Delivery Devices in Healthy Subjects

Study NCT00709254

Study of Single and Multiple Doses of Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Healthy Subjects (LEF-2495)

Study 12960555

Analgesic efficacy of inhaled morphine in patients after bunionectomy surgery

Study 15366326

Safety and pharmacokinetics of inhaled morphine delivered using the AERx system in patients with moderate-to-severe asthma

Do we have the necessary experience?

We are very excited to have Igor Gonda on our team as our CSO. Igor, previously as President of Aradigm, invented an opioid inhaler named the AERx  (pronounced Erics) and with it completed phase 1, phase 2 and phase 2b clinical trials. This was 20 years ago when there was no opioid crisis, and Igor was clearly ahead of his time. Despite the proven safety and efficacy and the patient acceptance, there was a still missing piece of the puzzle needed to make an opioid inhaler commercially viable – it needed a value-added proposition that could justify the added expense of the hardware over the cost of pills. That is where RevMD comes in. By making the inhaler a connected health device adding authentication and compliance reporting, we expect to add the necessary value will make the inhaler commercially viable. 

The Building Block Approach

We are not inventing a new product; we are assembling already-existing building blocks.

Our level of difficulty is not in inventing something new. The technologies we need already exist in many forms. Our value-added is that we are assembling them in a new way. Therefore, we have plenty of technologies to choose from, and we need only to select the appropriate technologies that meet our requirements and fit within our constraints.

Our level of difficulty is in implementing within a regulatory framework and reliably supporting this user base at scale; therefore, prior large-scale implementation experience and judicious selection of technologies to meet volume and integrity requirements are key. This task would be daunting without sufficient experience and appropriate selection of methodologies and technologies.


  • The AERX* opioid inhaler invented by our Chief Science Officer Igor Gonda has previously passed phase II clinical trials
  • OOB (out-of-the-box) solutions are available for fingerprint authentication
  • IoT networks are evolving and there are many choices for this technology
  • Devising our SaMD ECC processing is an extension of existing modeling methodologies and technologies.

Contact us for more information

Or call — 865 329-6792

8 + 7 =

Better Health Care is Our Mission

Re-inventing pharmaceutical delivery systems, for you.

(865) 329 6792

5600 Crooked Pine Lane Knoxville, TN 37921